| Budget Amount *help |
¥14,430,000 (Direct Cost: ¥11,100,000、Indirect Cost: ¥3,330,000)
Fiscal Year 2018: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2017: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2015: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
|---|
| Outline of Final Research Achievements |
Apolipoprotein CIII (apoCIII) is a constituent of all lipoproteins except LDLs and mediates the metabolism of triglyceride (TG)-rich lipoproteins through inhibition of LPL activity. Elevated plasma levels of apoCIII are directly correlated with the plasma TG and increase the cardiovascular risk. However, the pathophysiological functions of apoCIII in vivo have not been fully elucidated. To examine the functional roles of apoCIII in lipoprotein metabolism and atherosclerosis, we generated both trangesgenic (Tg) and apoCIII knockout (KO) rabbits. Tg rabbits showed high levels of plasma TG whereas apoCIII KO rabbits exhibited lower plasma levels of TG than those of wild-type (WT) rabbits while total cholesterol and HDL-cholesterol levels were unchanged. Analysis of lipoproteins revealed that reduced plasma TG levels in KO rabbits were accompanied by significant reduction of VLDLs and intermediate-density lipoproteins (IDLs).
|
